In tyrosol-treated NAFLD mice, Pparα, Cpt1a, and Acadm genes were upregulated, as well as PPARα and ACOX1 proteins, which were increased with respect to untreated mice, whereas gene expression of Scd1 and Srebp-1c was reduced, confirming previous evidence demonstrating that tyrosol increases hepatic lipid oxidation and inhibits lipogenesis [10]. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.